Hemodynamics and Congestion in Heart Failure: A Poster Session Review | Physician Update 2020 | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/2020/hemodynamics-and-congestion-in-heart-failure-poster-session-review/
Ashley Hardin, M.D., reviewed the "Hemodynamics and Congestion in Heart Failure" poster session from the 2020 AHA Scientific Sessions.
Physician Update 2021 | Physician Update 2022 | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/2021/
Review reports of our physicians and scientists from the 2019 AHA Scientific Sessions.
Physician Update 2022 | Clinical Heart and Vascular Center | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/
Review reports of our physicians and scientists from the 2019 AHA Scientific Sessions.
Test Review Date | UT Southwestern Medical Center
https://utswmed.org/test-review-date/
Test Review Date
Physician Update 2020 | Physician Update 2022 | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/2020/
Physician Update 2020
Physician Liaisons | Physician Resources | UT Southwestern Medical Center
https://utswmed.org/physician-resources/physician-liaisons/
Physician Liaisons
Physician Update 2019 | Physician Update 2022 | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/2019/
Physician Update 2019
Physician Update 2018 | Physician Update 2022 | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/2018/
Physician Update 2018
Physician Referrals & Transfers | Physician Resources | UT Southwestern Medical Center
https://utswmed.org/physician-resources/physician-referrals-transfers/
Physician Referrals & Transfers
Effects of Linagliptin on Heart Failure and Related Outcomes: Observations from the CARMELINA Trial | Physician Update 2018 | UT Southwestern Medical Center
https://utswmed.org/heart/physician-update/2018/effects-linagliptin-heart-failure-and-related-outcomes-observations-carmelina-trial/
UT Southwestern doctors reported results from the HF analyses of CARMELINA, demonstrating no difference in any HF-related outcome with linagliptin versus placebo.